Clinical breast cancer最新文献

{"title":"Lack of Mechanistic Validation in Breast Cancer: Necessity of NF-κB Remains Unclear.","authors":"Chengying Shao","doi":"10.1016/j.clbc.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.004","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI Features and Apparent Diffusion Coefficient Histogram-Based Nomogram for Classifying MRI-Only Suspicious Breast Lesions.","authors":"Xue Li, Lei Jiang, Jiayin Gao, Dandan Zheng, Hong Wang, Min Chen","doi":"10.1016/j.clbc.2025.04.003","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.04.003","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to develop and validate a nomogram integrating clinicoradiologic features and apparent diffusion coefficient (ADC)-based histogram parameters for MRI-only suspicious lesions.</p><p><strong>Methods: </strong>Ninety patients with MRI-detected suspicious lesions, who underwent breast MRI between May 2017 and August 2023, were retrospectively included and randomly assigned to a training cohort (n = 62) and a validation cohort (n = 28). Clinical and MRI data for each patient were reviewed and analyzed. Mean ADC values were computed using small two-dimensional region of interest measurements from ADC maps, followed by histogram analysis of the ADC maps, yielding 17 extracted histogram parameters. Univariate and multivariate logistic regression analyses identified significant variables associated with malignancy, which were incorporated into the nomogram. The diagnostic performance of these variables and the nomogram was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC) and DeLong's test.</p><p><strong>Results: </strong>Univariate analysis revealed significant differences between malignant and benign groups in terms of margin, kinetic pattern, mean ADC, and four ADC histogram parameters (ADC energy, ADC entropy, ADC range, and ADC uniformity) (all P < .05). Multivariate analysis identified kinetic pattern (P = .005, odds ratio [OR] = 2.569) and ADC entropy (P = .003, OR = 6.687) as significant predictors of MRI-only suspicious lesion classification. The nomogram combining kinetic pattern and ADC entropy demonstrated a C-index of 0.820 (95% confidence interval [CI]: 0.714-0.927) in the training cohort and 0.728 (95% CI: 0.528-0.878) in the validation cohort.</p><p><strong>Conclusions: </strong>This nomogram, integrating kinetic pattern and ADC entropy, provides a simple, noninvasive tool for classifying MRI-only suspicious lesions, offering superior performance compared to mean ADC values.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Lymph Node Involvement in Clinically Node-Negative Breast Cancer Following Neoadjuvant Chemotherapy: Rationale for Selective Omission of Sentinel Lymph Node Biopsy.","authors":"Arith Reyes, Roshni Rao, Lisa Wiechmann, Luona Sun, Stacy Ugras, Bret Taback","doi":"10.1016/j.clbc.2025.03.021","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.021","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy (NAC) is now frequently utilized for earlier stage breast cancer. Historically, removing axillary lymph nodes (LN) has guided treatment decisions and reduced regional recurrence, yet its utility in clinically node-negative (cN0) patients following NAC has yet to be elucidated. This study evaluated the incidence of residual occult pathologic nodal disease after NAC in cN0 breast cancer and associated clinicopathologic risk factors.</p><p><strong>Methods: </strong>A retrospective study of 249 cN0 patients who received NAC at our institution from 2010-2021 was performed. Clinical and pathologic tumor features were compared between 2 groups: persistent LN- versus LN+ after NAC.</p><p><strong>Results: </strong>The study group comprised 166 patients: 19 (11.4%) had pathologic LNs positive following NAC. Patients with LN+ (n = 19) versus LN- (n = 147) had greater mean clinical tumor size (P < .01), higher clinical T stage (P < .001), invasive lobular cancer (P < .01), lymphovascular invasion (P 0.01), and ER+ HER2- phenotype (P < .01). Conversely, LN- patients more likely had HER2+ tumors (P < .01) and in-breast pathologic complete response (P < .05). Sentinel LN biopsy (SLNB) obtained a mean of 3.8 LNs with 2 (1.2%) patients having ≥ypN2. At 46 months median follow-up, 1 (0.6%) axillary recurrence occurred.</p><p><strong>Conclusions: </strong>There is a low incidence of both residual occult disease in the axilla and axillary recurrence in cN0 breast cancer patients following NAC. Many of these patients may avoid axillary surgery, or at a maximum, undergo SLNB alone with low concern for axillary recurrence.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Trial Comparing Ultrasound Guided Modified Pectoral Block Versus Erector Spinae Block for Post Mastectomy Pain Management: A Comparative Analysis.","authors":"Annet Susan Abraham, Punit Mehta, Gautam Girotra, Neeraj Yadav","doi":"10.1016/j.clbc.2025.03.023","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.023","url":null,"abstract":"<p><strong>Background: </strong>The modified pectoral nerve (PECS) block is an established technique for providing surgical anesthesia and postoperative analgesia during breast surgery. The erector spinae plane block (ESP), has also been demonstrated to provide extensive multidermatomal sensory block. Our study compared the efficacy and safety of both these USG guided blocks for postoperative analgesia after Modified Radical Mastectomy (MRM).</p><p><strong>Methods: </strong>80 adult female patients (ASA grades I and II) undergoing MRM were randomly allocated into 2 groups. Group P received modified PECS block, whereas group E received ESP block using same volume and concentration of 0.375% levobupivacaine (30 mL) after induction of anaesthesia. Fentanyl was used for postoperative pain relief via patient-controlled analgesia (PCA) pumps which was set with fentanyl boluses of 25 mcg, time out interval at 15 minutes and no basal infusion.</p><p><strong>Results: </strong>The quality of analgesia was significantly better in patients receiving modified PECS block compared with ESP block. Total fentanyl consumed at the end of 24 hrs was significantly lesser in group P (160.85 ± 50.6 mcg) as compared to group E. (235.37 ± 88.42 mcg) (p < .001). At 24 hours postoperatively, mean NRS scores in group P were significantly lower than group E (1.18 ± 1.13 vs. 2.65 ± 0.98) (p < .001). Patients who received modified PECS block had better pain relief and sleep at night compared to group E (p < .001) which was assessed via a Likert scale questionnaire. Interestingly enough, the ease of both abduction and adduction of arm was found to be significantly better in group E as compared to group P at 12 hours (p = .001) and 24 hours (p = .005) postoperatively.</p><p><strong>Conclusions: </strong>We found that while the modified PECS block offered better postoperative pain relief, the ESP block facilitated physiotherapy, although this advantage was achieved at the cost of less effective pain management. Both blocks showed no adverse effects.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Features and Predictive Model for Mixed Invasive Ductal and Lobular Breast Carcinoma in Early-Stage Patients.","authors":"Yongxin Li, Yinyin Ye, Xinlong Tao, Xiao Liang, Xingchang Qiu, Jiuda Zhao","doi":"10.1016/j.clbc.2025.03.019","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.019","url":null,"abstract":"<p><strong>Introduction: </strong>Mixed invasive ductal and lobular breast carcinoma (IDLC) is a rare and understudied subtype of breast cancer with unique prognostic characteristics.</p><p><strong>Methods: </strong>This study analyzed data from the SEER database and the METABRIC database. Survival outcomes of IDLC were compared with those of IDC and ILC using Kaplan-Meier survival curves and Cox regression analyses. Based on these findings, a prognostic model tailored for IDLC patients was developed using the SEER cohort, which was divided into a training set (70%) and an internal validation set (30%). The model incorporated clinical and molecular features and was externally validated using the METABRIC cohort. Its performance was assessed via C-index, AUC, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 26,138 early-stage IDLC patients were included, along with 391,888 IDC and 47,571 ILC patients. In unadjusted analyses, IDLC showed better overall survival (OS) and breast cancer-specific survival (BCSS) compared to both IDC and ILC. However, after multivariate adjustment, the differences in survival outcomes varied. IDLC demonstrated better OS than IDC and better BCSS than ILC. Additionally, a prognostic model for early-stage IDLC that incorporates clinical and molecular features was developed.</p><p><strong>Conclusion: </strong>This study found that early-stage IDLC had superior BCSS and OS in unadjusted analyses. However, after multivariate adjustment, there was no difference in BCSS between IDLC and IDC, and no difference in OS between IDLC and ILC. A prognostic model was developed and validated, offering precise predictions of OS and BCSS.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Breast Cancer Treatment and Cardiac Events: A Systematic Review.","authors":"Nicolas Meillan, Sofia Rivera, Stéphane Ederhy, Anna Gueiderikh, Assia Lamrani-Ghaouti, Florent De Vathaire, Rodrigue Setcheou Allodji","doi":"10.1016/j.clbc.2025.03.018","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.018","url":null,"abstract":"<p><p>Cancer-treatment induced cardiovascular diseases are a concern in early breast cancer, especially when radiation is involved and systemic treatments may contribute. Our primary objective was to estimate the frequency of cardiac adverse events after early breast cancer treatment. We performed a systematic review on cardiac events after early breast cancer treatment, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, by searching PubMed, Scopus and Web of Science and cross-checking references from international guidelines on breast cancer treatment and cardio-oncology. Eighty-one studies were selected. Reporting of cardiac events and dose parameters was heterogeneous among studies due to the variability of the events being considered, follow-up duration and patient's age (most reported less than 5% with some as high as 34% at a maximum follow-up of 28 years). The most frequent are ischemic and valvular heart disease. Radiation modalities (hypofractionation, boost, partial or nodal irradiation) do not seem to change the risk of cardiac events. Anthracycline and aromatase inhibitors increase long-term cardiac risk, whereas anti-HER2-related effects are mostly transient. Myocardites with immunotherapy are rare (<1%) but follow-up is short. Other chemotherapy agents and poly(adenosine-diphosphate-ribose)-polymerase inhibitors have not been shown to increase cardiac risks which is reduced with more recent treatments, and increased by young age at diagnosis and previous cardiac risk factors. Advances in treatment seem to lower cardiac events. Prospective studies with exhaustive reporting of toxicity and radiotherapy features are warranted as well as the help of a cardio-oncologist to manage risk factors.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Axillary Management in Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy.","authors":"Samir Mitri, Laura Martin Manfroi, Prabh R Pannu, Jessica Means, Estefania Roldan-Vasquez, Giulia Borgonovo, Tarbia Hamid, Hiral Thakkar, Roger B Davis, Ted A James","doi":"10.1016/j.clbc.2025.03.020","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.020","url":null,"abstract":"<p><strong>Introduction: </strong>Triple-negative breast cancer (TNBC) often shows significant response to neoadjuvant chemotherapy (NACT), creating opportunities for axillary de-escalation. This study investigates axillary de-escalation and the factors influencing its use in TNBC.</p><p><strong>Methods: </strong>Patients with cT1-cT2, cN1 TNBC treated between 2012 and 2020 were identified from the National Cancer Database. Nodal response rates, including achievement of ypN0, were analyzed. Logistic regression identified clinical and sociodemographic factors associated with axillary management.</p><p><strong>Results: </strong>Among 12,742 patients undergoing axillary lymph node dissection (ALND), 31.7% achieved nodal pathologic complete response (pCR). These patients were more also likely to achieve breast tumor pCR. Treatment across multiple facilities was associated with a higher likelihood of attempted axillary de-escalation. ALND rates steadily declined between 2014 and 2020.</p><p><strong>Conclusion: </strong>Despite achieving nodal pCR after NACT, many patients with TNBC underwent ALND. These findings underscore the need to refine criteria and increase adoption of axillary de-escalation strategies in TNBC.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive AI-Based Approach in Classifying Breast Lesions: Focusing on Improving Pathologists' Accuracy and Efficiency.","authors":"Maryam Tahir, Yan Hu, Himani Kumar, Nada Shaker, David Kellough, Shaya Goodman, Manuela Vecsler, Giovanni Lujan, Wendy L Frankel, Anil V Parwani, Zaibo Li","doi":"10.1016/j.clbc.2025.03.016","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.016","url":null,"abstract":"<p><strong>Background: </strong>Accurate classification of breast lesions is essential for effective clinical decision-making and patient management. In this study, we evaluated an artificial intelligence (AI) solution to classify whole slide images (WSIs) of breast lesions.</p><p><strong>Methods: </strong>We analyzed a cohort of 104 breast cases, including 20 invasive carcinomas, 4 microinvasive carcinomas, 15 ductal Carcinoma in situ (DCIS) cases, and 65 lobular neoplasia/benign cases. The AI's performance was compared with the ground truth established by breast pathologists.</p><p><strong>Results: </strong>For invasive carcinoma, it achieved an area under the curve (AUC) of 0.976, with sensitivity and specificity of 91.7% (84.4%, 95.4%) and 95% (88.0% 97.3%) respectively. For DCIS, the AUC was 0.976, with sensitivity and specificity of 93.3% and 96.6%. For lobular neoplasm, it achieved an AUC of 0.953, sensitivity of 94.1%, and specificity of 95.8%. The AI also performed well in detecting microcalcifications, with an AUC of 0.925 and sensitivity of 95%. Pathologists' diagnostic accuracy improved from 97.1% to 100% with AI support (303 vs. 312 accurate case reads per arm). Additionally, the AI use significantly enhanced the pathologists' efficiency, reducing their review time by an average of 16.5% across the 3 pathologists and led to a 33% reduction in immunohistochemistry usage.</p><p><strong>Conclusion: </strong>This study highlights the potential of AI in breast lesion classification, demonstrating high sensitivity, specificity, and efficiency, and supports its integration into routine pathology practice.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Five-Item Modified Frailty Index (mFI-5) Predicts Adverse Short-term Outcomes in Patients Undergoing Mastectomy: A Propensity Score-Matched Analysis of 252,054 Cases.","authors":"Felix J Klimitz, Fortunay Diatta, Joshua Freeman, Thomas Schaschinger, Stav Brown, Samuel Knoedler, Gabriel Hundeshagen, Martin Kauke-Navarro, Bohdan Pomahac, Adriana C Panayi","doi":"10.1016/j.clbc.2025.03.015","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.015","url":null,"abstract":"<p><strong>Background: </strong>Frailty has emerged as a critical predictor of postoperative outcomes, particularly in older surgical patients. However, its role in mastectomy patients remains underexplored. This study evaluates the utility of the 5-item Modified Frailty Index (mFI-5) in predicting 30-day postoperative complications in mastectomy patients, aiming to improve risk stratification and inform clinical decision-making.</p><p><strong>Methods: </strong>A retrospective analysis using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was conducted from 2008 to 2022. Patients were categorized into high-risk (mFI-5 ≥ 2) and low-risk (mFI-5 < 2) groups. Propensity score matching (PSM) was applied to create balanced cohorts and multivariate logistic regression was used to evaluate associations between frailty and postoperative outcomes.</p><p><strong>Results: </strong>Of the 252,054 adult female patients who underwent mastectomy, 1.2 % were identified as high-risk frail. High-risk patients were older (70 ± 9.9 vs. 60 ± 14 years, P < .001) and had a higher BMI (35 ± 9.1 vs. 29 ± 7.1 kg/m², P < .001) compared to low-risk patients. After PSM, high-risk patients had significantly higher odds of any complication (OR: 2.05, 95 % CI: 1.70-2.47, P < .001), surgical complications (OR: 1.70, 95 % CI: 1.38-2.10, P < .001), and medical complications (OR: 3.81, 95 % CI: 2.64-5.50, P < .001). Key complications included infections, bleeding requiring transfusion, and unplanned readmissions.</p><p><strong>Conclusion: </strong>The mFI-5 effectively identifies mastectomy patients at higher risk of postoperative complications, including medical complications and unplanned reoperation or readmission, underscoring its value in preoperative risk stratification. Incorporating frailty assessments into clinical practice could enhance surgical decision-making, optimize resource allocation, and improve patient outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of TissuGlu in Reducing Seroma Formation and Postoperative Recovery in Mastectomy Patients: A Systematic Review and Meta-Analysis of Comparative Studies.","authors":"Daniel Madarshahian, Kwaku Duah-Asante, Hadyn Kn Kankam, Joanna Skillman","doi":"10.1016/j.clbc.2025.03.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.03.014","url":null,"abstract":"<p><p>Postmastectomy complications, especially seroma formation, pose significant challenges to recovery and patient outcomes. TissuGlu, a lysine-urethane-based tissue adhesive, has been proposed as an alternative to standard wound closure (SWC) with drains to reduce seroma incidence and enhance recovery. However, its effectiveness remains debated. This meta-analysis assesses TissuGlu's impact compared to SWC in postmastectomy wound management. Following PRISMA guidelines, a systematic review and meta-analysis were conducted, including randomized controlled trials (RCTs) and observational studies published through August 2024 from databases including PubMed, Cochrane Library, Google Scholar, Embase, and Scopus. Six studies involving 408 patients (450 mastectomies) met inclusion criteria. Results indicated a significantly higher seroma incidence in the TissuGlu group than SWC (OR = 2.57, 95% CI, 1.20-5.52, P = .02), while no significant difference was observed in the number of mastectomies requiring aspiration (OR = 1.01, 95% CI, 0.29-3.51, P = .98). SWC showed benefits in fewer aspirations per mastectomy (WMD = 0.87, P = .003) and reduced aspiration volume (WMD = 110.83 mL, P = .04). TissuGlu notably reduced hospital stays (WMD = -2.44 days, P < .00001), suggesting improved recovery times. While SWC may better control postoperative fluid accumulation, TissuGlu holds promise in minimizing drain duration. Further high-quality RCTs are needed to establish the optimal role of TissuGlu, potentially in conjunction with drains, for improved postmastectomy outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}